<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884663</url>
  </required_header>
  <id_info>
    <org_study_id>01-47-7006-2008</org_study_id>
    <secondary_id>2008-002312-17</secondary_id>
    <nct_id>NCT00884663</nct_id>
  </id_info>
  <brief_title>Candesartan Versus Propranolol for Migraine Prevention</brief_title>
  <official_title>Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kragerø Tablettproduksjon as, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the present study is to compare candesartan with propranolol for migraine
      prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Candesartan was shown to be effective for migraine prophylaxis in a randomized double blind
      cross-over study published in 2003. The drug is now widely used for this purpose in many
      countries, although no confirmatory study has been published. The aims of the present study
      are: 1) to see if the results in the first candesartan study can be replicated in a new
      patient population, including patients with chronic migraine, and, 2) to perform a
      head-to-head comparison of candesartan 16 mg/day with standard treatment with propranolol 160
      mg slow release. We also intend to study whether responsiveness to these drugs may be related
      to heart rate variability and baroreceptor sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of days per 4 weeks with moderate or severe headache lasting ≥ 4 hours or is treated with the patient's usual headache medication</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days with headache</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hours with headache</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache intensity (0-3 scale) on days with headache</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of analgesics</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of triptans</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with sick leave</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders (≥ 50% decrease in migraine days compared with baseline)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of reported side effects</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of predefined retrospective side effects</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Migraine Without Aura</condition>
  <condition>Migraine With Aura</condition>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>1 Candesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>Candesartan cilexitil tablets, 16 mg once daily</description>
    <arm_group_label>1 Candesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>Propranolol hydrochloride capsules 160 mg once daily, slow release formulation</description>
    <arm_group_label>2 propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets and capsules</description>
    <arm_group_label>3 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 65 years

          -  retrospectively have ≥ 2 migraine attacks per month during the last 3 months

          -  during the baseline period have ≥ 2 migraine attacks

          -  debut of migraine at least one year prior to inclusion

          -  start of migraine before age 50 years.

        Exclusion Criteria:

          -  interval headache not distinguishable from migraine

          -  chronic tension-type headache or other headache occurring on ≥ 15 days/month

          -  pregnancy, nursing or inability to use contraceptives

          -  heart conduction block on ECG or significant ECG abnormality on inclusion

          -  heart rate &lt; 54 after 3 minutes rest

          -  previous or present asthma, diabetes; decreased hepatic or renal function

          -  hypersensitivity to active substance

          -  history of angioneurotic edema

          -  significant psychiatric illness

          -  use of daily migraine prophylactics less than 4 weeks prior to start of study

          -  having tried ≥ 3 prophylactic drugs against migraine during the last 10 years

          -  previous use of propranolol or candesartan in adequate doses

          -  previous discontinuation of either Atacand or Inderal Retard (or another beta blocker)
             due to side effects

          -  current use of antihypertensive medication

          -  require use of rizatriptan (Maxalt) 10 mg tabl.

          -  subjects requiring detoxification from acute medication (ergotamines, opioids)

          -  patients who consistently fail to respond to any acute migraine medication

          -  patients with alcohol or illicit drug dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars J Stovner, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian National Headache Centre, St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars J Stovner, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian National Headache Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norwegian National Headache Centre, St. Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7489</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1;289(1):65-9.</citation>
    <PMID>12503978</PMID>
  </reference>
  <results_reference>
    <citation>Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014 Jun;34(7):523-32. doi: 10.1177/0333102413515348. Epub 2013 Dec 11.</citation>
    <PMID>24335848</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>December 22, 2013</last_update_submitted>
  <last_update_submitted_qc>December 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

